The Wnt signaling pathway and related therapeutic drugs in Autism Spectrum Disorder
Seung Min Bae 1*, Ji Yeon Hong 2
1Gachon University Gil Medical Center, 2Yonsei University College of Medicine
Received: July 27, 2017; Revised: September 27, 2017; Accepted: September 27, 2017; Published online: September 27, 2017.
© The Korean College of Neuropsychopharmacology. All rights reserved.

Abstract
Autism spectrum disorder (ASD) is a series of neurodevelopmental disorder with a large genetic component. However, the pathogenic genes and molecular mechanisms of ASD have not been clearly defined. Recent technological advancements, such as next-generation sequencing, have led to the identification of certain loci that is responsible for the pathophysiology of ASD. Three functional pathways, such as chromatin remodeling, Wnt signaling and mitochondrial dysfunction are potentially involved in ASD. In this review, we will focus on recent studies of the involvement of Wnt signaling pathway components in ASD pathophysiology and related drugs used in ASD treatment.
Keywords: Autism Spectrum Disorder, Wnt, beta-catenin, chromodomain helicase DNA binding protein 8, neuronal development


e-submission

Archives